Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The quick ratio (acid-test) is N/A as of Tuesday, October 6, 2026.
QUICK RATIO (ACID-TEST)
N/A
Market Cap
$867.60M
Quick Ratio (Acid-Test)
9.52
TTM Avg
4.26
3Y Avg
6.09
5Y Avg
7.80
Market Cap
$856.30M
Quick Ratio (Acid-Test)
14.93
TTM Avg
20.63
3Y Avg
16.30
5Y Avg
22.70
Market Cap
$852.55M
Quick Ratio (Acid-Test)
7.96
TTM Avg
6.81
3Y Avg
6.62
5Y Avg
6.62
Market Cap
$837.43M
Quick Ratio (Acid-Test)
3.15
TTM Avg
4.21
3Y Avg
3.84
5Y Avg
4.13
Market Cap
$903.13M
Quick Ratio (Acid-Test)
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
Market Cap
$819.44M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.02
3Y Avg
3.56
5Y Avg
3.80
Market Cap
$915.95M
Quick Ratio (Acid-Test)
1.17
TTM Avg
1.03
3Y Avg
0.92
5Y Avg
1.05
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | 9.52 | 4.26 | 6.09 | 7.80 |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | 14.93 | 20.63 | 16.30 | 22.70 |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | 7.96 | 6.81 | 6.62 | 6.62 |
| Alumis Inc. (ALMS)vs › | $844.28M | 6.74 | 5.17 | 5.15 | 5.15 |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | 3.15 | 4.21 | 3.84 | 4.13 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | 16.16 | 3.88 | 3.97 | 4.50 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | 3.86 | 4.02 | 3.56 | 3.80 |
| Bioventus Inc. (BVS)vs › | $915.95M | 1.17 | 1.03 | 0.92 | 1.05 |
| InMode Ltd. (INMD)vs › | $812.20M | 7.28 | 9.00 | 9.42 | 9.03 |
Quick Ratio
N/A
Excludes inventory
Current Ratio
N/A
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
